LenioBio partners with AffinityAI to accelerate discovery of novel complex proteins through AI-guided design and high-throughput cell-free expression

"We have reinvented cell-free protein expression to fully harness the power of AI-driven protein design", said André Goerke, CEO of LenioBio. "ALiCE® combines the openness and flexibility of a cell-free system with the scalability of cell-based platforms. Together with AffinityAI, we can accelerate discovery cycles and bring precision-designed protein therapeutics to development much faster." " We have reinvented cell-free protein expression to fully harness the power of AI-driven protein...

Germany, 03/09/2025 (informazione.news - comunicati stampa - salute e benessere)

" said André Goerke, CEO of LenioBio.

AffinityAI specializes in the in-silico design of high-affinity, stable binding proteins called Designerbodies™. Unlike conventional antibodies, Designerbodies™ are designed with predefined binding sites, offering superior precision and control. These designs will be rapidly screened and optimized using ALiCE®, creating an automated, high-throughput pipeline for next-generation protein products for drug development, diagnostics, and biomedical research.

" said Timothy P. Jenkins , PhD, Head of Data Science and Associate Professor at DTU Bioengineering and CEO of AffinityAI. ."

This collaboration marks a significant step forward in accelerating the development of novel protein therapeutics, combining cutting-edge AI design with scalable, cell-free expression technology.

LenioBio GmbH is a biotechnology company pioneering cell-free protein expression with its ALiCE® platform, enabling rapid discovery, development, and scalable production of proteins beyond the limits of living cells. Founded in Germany in 2016, LenioBio is headquartered in Düsseldorf with R&D and manufacturing facilities in Aachen. Learn more at www.leniobio.com and follow LenioBio on LinkedIn.

AffinityAI is a Danish biotechnology company specializing in AI-guided protein design. Its proprietary Designerbodies™ are fully synthetic, small proteins engineered to bind specifically to selected epitopes on target proteins. Designed and delivered significantly faster than traditional antibody discovery methods, Designerbodies™ have broad applications across drug development, diagnostics, and biomedical research. Headquartered in Copenhagen , AffinityAI works at the intersection of artificial intelligence and biotechnology to accelerate the next generation of therapeutic innovation. Learn more at affinityai.dk .

Media Contact:

Akanksha Ranjit
Marketing & Communications
LenioBio GmbH
a.ranjit@leniobio.com

Logo - https://mma.prnewswire.com/media/2735875/5486611/LenioBio_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/leniobio-partners-with-affinityai-to-accelerate-discovery-of-novel-complex-proteins-through-ai-guided-design-and-high-throughput-cell-free-expression-302543824.html